Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
All Keywords
【초록키워드】 Ivermectin, SARS-CoV-2, Efficacy, randomized trial, outcome, Patient, In-vitro, High-dose, Standard dose, shown, receiving, groups, severe COVID-19 patient, 【제목키워드】 Ivermectin, Efficacy, Standard dose, severe COVID-19 patient,
【초록키워드】 Ivermectin, SARS-CoV-2, Efficacy, randomized trial, outcome, Patient, In-vitro, High-dose, Standard dose, shown, receiving, groups, severe COVID-19 patient, 【제목키워드】 Ivermectin, Efficacy, Standard dose, severe COVID-19 patient,